Primary and secondary outcomes
sleepiness, itching, burning sensation, headache, neck pain, scalp pain
SKIN REDNESS
Based on the tDCS target of UE M1 with electrode locations over C3 and C4, the primary efficacy outcome was the change in FMA-UE scores assessing UE mobility [For the safety outcome, the Adverse Effects Questionnaire was used after each tDCS session, which includes 11 questions about occurrence of headache, neck pain, scalp pain, tingling, itching, burning sensation, skin redness, sleepiness, trouble concentrating, acute mood change, or other specified conditions [